Thromboelastographic Analysis of Patients Receiving Aprotinin with Comparisons to Platelet Aggregation and Other Assays

• References

• 1 van Oeveren W, Kazatchkine MD, Descamps-Latscha B. Deleterious effects of cardiopulmonary bypass: A prospective study of bubble versus membrane oxygenation. J Thorac Cardiovasc Surg 97: 235-239 1989;
• 2 Musial J, Niewiarowski S, Hershock D, Morinelli TA, Coleman RW, Edmunds Jr LH. Loss of fibrinogen receptors from platelet surface during simulated extracorporeal circulation. J Lab Clin Med 105: 514-522 1985;
• 3 Wenger RK, Lukasiewicz H, Mikuta BS, Niewiarowski S, Edmunds LH. Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 97: 235-239 1989;
• 4 Zilla P, Fasol R, Groscurth P, Klepetko W, Reichenspurner H, Wolner E. Blood platelets in cardiopulmonary bypass operations: Recovery occurs after initial stimulation, rather than continual activation. J Thorac Cardiovasc Surg 97: 379-388 1989;
• 5 Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open heart surgery. Lancet 2: 1289-1291 1987;
• 6 Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with highdose aprotinin (Trasylol). J Thorac Cardiovasc Surg 97: 364-372 1989;
• 7 Dietrich W, Spannagl M, Jochum M, Wendt P, Schramm W, Barankay A, Sebening F, Richter JA. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology 73: 1119-1126 1990;
• 8 van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CRH. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 99: 788-797 1990;
• 9 Lavee J, Savion N, Smolinsky A, Goor DA, Mohr R. Platelet protection by aprotinin in cardiopulmonary bypass: Electron microscopic study. Ann Thorac Surg 53: 477-481 1992;
• 10 Lavee J, Raviv Z, Smolinsly A, Savion N, Varon D, Goor DA, Mohr R. Platelet protection by low-dose aprotinin in cardiopulmonary bypass: Electron microscopic study. Ann Thorac Surg 55: 114-119 1993;
• 11 Cosgrove III DM, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LAR, Stewart RW, McCarthy PM, Loop FD. Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study. Ann Thorac Surg 54: 1031-1038 1992;
• 12 Najman DM, Walenga JM, Fareed J, Pifarre R. Effects of aprotinin on anticoagulant monitoring: Implications in cardiovascular surgery. Ann Thorac Surg 55: 662-666 1993;
• 13 Zuckerman L, Cohen E, Vagher JP, Woodward E, Caprini JA. Comparison of thromboelastography with common coagulation tests. Thromb Haemostas 46: 752-756 1981;
• 14 Breddin K. Zur Messung der Thrombozytenadhäsivität. Thromb Diath Haemorh 12: 269-280 1964;
• 15 Mohr R, Golan M, Martinowitz U, Rosner F, Goor DA, Ramot B. Effect of cardiac operation on platelets. J Thorac Cardiovasc Surg 92: 434-441 1986;
• 16 Mohr R, Martinowitz U, Golan M, Luski A, Goor DA, Ramot B. Platelet size and mass as an indicator for platelet transfusion after cardiopulmonary bypass. Circulation 74 (Suppl 3) 153-158 1986;
• 17 Hunt BJ, Murkin JM. Heparin resistance after aprotinin. Lancet 341 1993; 126
• 18 Wendel HP, Heller W, Gallimore MJ, Bantel H, Miiller-Beissenhirtz H, Hoffmeister HE. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement. Blood Coagul Fibrinolysis 4: 41-45 1993;
• 19 Wang JS, Lin CY, Hung WT, O’Conner MF, Thisted RA, Lee BK, Karp RB, Yang MW. Thromboelastograph fails to predict postoperative hemorrhage in cardiac patients. Ann Thorac Surg 53: 435-439 1992;